Document is current
Any future updates will be listed below
-
Authors
Slotvitsky, M. M. https://orcid.org/0000-0003-2237-4217
Romanova, S. A. https://orcid.org/0000-0002-4223-0133
Dabizha, M. O. https://orcid.org/0009-0006-1695-1048
Alkhateeb, R. https://orcid.org/0009-0002-0533-8142
Agladze, K. I. https://orcid.org/0000-0002-9258-436X
Tsvelaya, V. A. https://orcid.org/0000-0002-3554-9736
- License Information
-
More Information
Article History
Received: 16 November 2024
Revised: 10 March 2025
Accepted: 11 March 2025
First Online: 13 June 2025
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
: The cell line used for referenced data was provided by the E. Meshalkin Novosibirsk Scientific Research Institute of Circulation Pathology and handling approved by the Institute of Circulation Pathology Ethics Committee (protocol no. 27, March 21, 2013). A pluripotent stem cells line was generated from cells donated by the patient without reported cardiovascular diseases. Written informed consent was obtained from the donor. All experiments and procedures in this study were performed in accordance with principles for human experimentation as defined in the 1964 Declaration of Helsinki and its later amendments and were approved by the Institutional Committee of M. F. Vladimirsky Moscow Regional Clinical Research Institute (protocol no. 4, March 4, 2021) and by the Moscow Institute of Physics and Technology Life Science Center Provisional Animal Care and Research Procedures Committee (protocol no. A2-2012-09-02). All applicable international, national, and/or institutional guidelines for the care and use of cell lines were followed.
: The authors of this work declare that they have no conflicts of interest.
